GILD · 8-K · 20260804PR000028
Guidance and Outlook
GILEAD SCIENCES, INC. · 2026-08-04 · Importance 95 · Surprise 92
Gilead raised its 2026 product-sales guidance to $30.1 billion-$30.4 billion from $30.0 billion-$30.4 billion previously. Product sales excluding Veklury guidance increased to $29.8 billion-$30.1 billion from $29.4 billion-$29.8 billion, while expected Veklury sales were reduced to approximately $300 million from approximately $600 million. GAAP diluted loss-per-share guidance was revised to $(3.75)-$(3.40), and non-GAAP diluted loss-per-share guidance improved to $(0.65)-$(0.30). The guidance includes approximately $9.08 per share from $11.1 billion of acquired IPR&D charges related to the Arcellx, Tubulis and Ouro Medicines transactions, net of the Lakefront collaboration and related taxes.